CD4 and breast carcinoma: Eleven studies [38], [40], [42], [46]–[48], [50], [52], [64], [66], [70] evaluated the effects of MBTs on CD4 in a total of 676 participants with diseases (HIV, breast cancer, and ulcerative colitis) and 101 healthy individuals.